Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Nov
20
Today In Oncology
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer
Newly Diagnosed AL Amyloidosis FDA Grants Traditional Approval to Regimen
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo